The incidences of HCC during the study period were analyzed by examination of medical records. Ten markers at starting point of this study were compared between patients with abnormal serum biomarkers levels, denoted as the positive groups, and those with normal levels, denoted as negative groups. The judgment criteria are as follows: ALB < 35 g/l, TBIL > 19 μmol/L, ALT > 40 U/L, PLT < 100 × 109/L, AFP > 10 ng/mL, PT(s) > 13 s, PT(a) < 75%, AFP-L3 > 1.0 ng/mL, GP73 > 150 ng/mL, and AFP-L3/AFP > 0.05. After 3 years' follow-up, cumulative incidence (CI) and relative risk (RR) of ten markers were calculated for each group to identify potential risk factors for HCC. A chi-square test was performed to compare the incidence rate between the positive and negative groups in our study cohort. All markers at starting point of this study were compared between patients who had developed HCC within 3 years and those who had not developed HCC to explore the early prediction value of serum markers. In order to investigate the dynamic change of the serum markers during the progression of HCC, we had compared all markers in HCC patients for two time points: starting point and the time they are diagnosed with HCC. Normally distributed data were analyzed with Student's t-tests. Other data were tested by the Wilcoxon method. To assess the role of all markers as diagnostic predictive markers for HCC, receiver operating characteristic curves (ROC) were plotted and the area under the curve (AUC) was calculated. All statistical analysis was performed using SPSS 14.0 software (SPSS, Inc., Chicago, IL).